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The endocytic pathway and therapeutic efficiency
of doxorubicin conjugated cholesterol-derived
polymers†
Sema Sevimli,a,b,c Sharon Sagnella,b,c Alexander Macmillan,c Renee Whan,c
Maria Kavallaris,b,c Volga Bulmusd and Thomas P. Davis*e,f
Previously synthesized poly(methacrylic acid-co-cholesteryl methacrylate) P(MAA-co-CMA) copolymers
were examined as potential drug delivery vehicles. P(MAA-co-CMA) copolymers were fluorescently
labelled and imaged in SHEP and HepG2 cells. To understand their cell internalization pathway endocytic
inhibition studies were conducted. It was concluded that P(MAA-co-CMA) are taken up by the cells via
clathrin-independent endocytosis (CIE) (both caveolae mediated and cholesterol dependent endocytosis)
mechanisms. The formation and characterization of P(MAA-co-CMA)–doxorubicin (DOX) nanocomplexes
was investigated by fluorescence lifetime imaging microscopy (FLIM), UV-Visible spectroscopy (UV-Vis)
and dynamic light scattering (DLS) studies. The toxicity screening between P(MAA-co-CMA)–DOX nano-
complexes (at varying w/w ratios) and free DOX, revealed nanocomplexes to exhibit higher cytotoxicity
towards cancer cells in comparison to normal cells. FLIM and confocal microscopy were employed for
investigating the time-dependent release of DOX in SHEP cells and the cellular uptake profile of P(MAA-
co-CMA)–DOX nanocomplexes in cancer and normal cell lines, respectively. The endocytic pathway of
P(MAA-co-CMA)–DOX nanocomplexes were examined in SHEP and HepG2 cells via flow cytometry
revealing the complexes to be internalized through both clathrin-dependent (CDE) and CIE mechanisms.
The drug delivery profile, reported herein, illuminates the specific endocytic route and therapeutic
efficiency of P(MAA-co-CMA)–DOX nanocomplexes strongly suggesting these particles to be promising
candidates for in vivo applications.
Introduction
Advanced drug delivery systems aim to enhance the efficacy of
traditional medicine by introducing new therapeutic strategies.
The moment a therapeutic is injected into the body, its medi-
cinal effect is somewhat hindered due to rapid elimination
triggered by renal excretion and/or hepatic metabolism; which
restricts the effective dose reaching the target sites. During
drug circulation throughout the body, accumulation at off-
target sites can cause toxicity leading to unwanted side
effects.1 Characteristic properties seen at target sites such as
pH and temperature gradients, the presence of specific
enzymes and receptors have been taken into account in the
process of designing delivery systems to overcome the non-
specific delivery issues.2–6 Nano-sized polymers containing
therapeutic entities like drugs, genes or peptides – with
enhanced targeted-delivery properties – have been established
as a credible option for clinical development. These nano-
scaled delivery vehicles offer significant advantages as they
enhance therapeutic efficiency by prolonging drug half-life,
improving solubility of hydrophobic entities, reducing
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potential immunogenicity, and/or releasing therapeutics in a
sustained or stimuli-triggered manner.7 Since the structure of
polymer carriers greatly influences the bioactivity of their
therapeutic cargos, an in depth understanding of cellular pro-
cessing and uptake mechanisms of polymer-drug complexes
will elucidate the rational design of polymers as effective drug
delivery systems.8,9
Endocytosis – a naturally occurring membrane-bound
internalization process observed in all cells – is responsible for
the uptake of polymer carriers.10,11 Based on the size and
material of the load, endocytosis can occur by different
mechanisms; (1) phagocytosis: the uptake of solid large par-
ticles specific to neutrophils and macrophages12 and (2) pino-
cytosis: known as fluid and solute-phase endocytosis which
transpires via macropinocytosis (internalizes particles up to
5 µm in size), clathrin-dependent (CDE) (up to 200 nm in size)
or clathrin-independent (CIE) endocytosis.10,13,14 Cholesterol-
dependent and caveolae-mediated pathways are subdivisions
of CIE. Caveolae (50-80 nm) are cholesterol and glycosphingo-
lipid rich microdomains on the cell membrane which are
involved in cholesterol homeostasis and glycosphingolipid
transport.15
Doxorubicin (DOX), a chemotherapeutic agent, has been
utilized in the treatment of various cancers including breast,
lung, multiple myeloma and lymphoma.16 While highly
effective, this well-known antitumor drug is associated with
challenges such as those caused by dose-limiting toxicity,
resistance mechanisms developed in cancer cells thereby redu-
cing drug uptake and cardiotoxicity.17 One of the many
approaches to overcome these limitations and enhance the
efficacy of DOX is by utilizing polymers as drug carriers.
Various polyanions such as polyglutamate;18 polyaspartate,19
poly(acrylic acid),20,21 γ-polyglutamic acid,22 block ionomers of
aspartate, benzyl glutamate23 and benzyl aspartate24 with poly-
(ethylene oxide) have demonstrated encouraging results in
terms of binding and delivering DOX into targeted cells and
tissues. Consequently, anionic poly(methacrylic acid-co-choles-
teryl methacrylate) P(MAA-co-CMA) copolymer series – com-
prised of enriched electrostatic binding abilities and pH-
responsive/membrane disruptive properties – were investigated
as potential DOX carriers.
The present study focuses on the ability of cholesterol-
derived ionic copolymers to effectively deliver DOX while con-
trolling its endocytic mechanism, enhancing its efficacy (vs.
free drug) in carcinoma cells and limiting its toxicity towards
normal cell lines, thereby overcoming one of the major
obstacles seen in advanced drug delivery systems. Accordingly,
the specific cell uptake profile and drug delivery efficiency of
P(MAA-co-CMA) copolymers (with varying CMA units) were
evaluated in carcinoma and normal cells. The physicochemical
properties – such as charge, size and toxicity profile – of
P(MAA-co-CMA)–DOX nanocomplexes as well as their thera-
peutic efficacy were evaluated. The cellular internalization
mechanism of both polymers and nanocomplexes were
assessed in terms of determining their specific endocytic route
via flow cytometry and living cell confocal microscopy.
Results and discussion
Modification and fluorescent labelling of P(MAA-co-CMA)
To visualize the cellular internalization profile of both the
copolymers and nanocomplexes; P(MAA-co-CMA) copolymer
series were fluorescently tagged with Alexa Fluor® 488. The
carboxylate groups on P(MAA-co-CMA) were tailored into stable
amide bonds prior to chemical labelling applications. 2 mol%
of the carboxylate groups on each P(MAA-co-CMA) sample was
targeted and modified according to the protocol described in
literature.25 Carboxylates were reacted with N-hydroxysulfosuc-
cinimide (NHS-sulfo) in the presence of ethyl (dimethylamino-
propyl) carbodiimide (EDC), resulting in a semi-stable NHS-
sulfo ester intermediate. The amine-reactive NHS ester groups
were then reacted with cystamine dihydrochloride forming a
stable amide bond (Scheme S1, ESI†). This modification was
characterized via H1 NMR and FTIR spectroscopy; however the
NMR spectrum failed to illustrate the chemical-bond changes
in the polymer due to the overlapping broad-D2O peak. Alter-
natively, FTIR spectroscopy revealed alterations in the polymer
structure as indicated by a significant reduction in the inten-
sity of the distinctive carboxylic acid O–H (3400–2900 cm−1)
and CvO (1630–1550 cm−1) stretch and the appearance of
peaks between 1650–1580 (N–H bend) and 1020-1220 (ali-
phatic amines) (Fig. 1-A).
The modified polymer was then labelled with the fluo-
rescent maleimide dye, Alexa Fluor® 488. The Beer–Lambert
Law (A = ε × b × C; where A is the absorbance, ε is extinction
coefficient (M cm−1), b is wavelength (cm) and C is the concen-
tration (M)) was employed for calculating the final fluorescent
dye content on each polymer via UV-Visible spectroscopy. The
extinction coefficient (ε) for each copolymer (at 275 nm
specific for cholesterol, in MilliQ water) was obtained from a
calibration curve of standard P(MAA-co-CMA) solutions in
MilliQ water (Fig. 1-B). Using the ε values of copolymers and
Alexa Fluor® 488 dye (ε = 71 000 M cm−1) the final concen-
trations of both components in the modified structure were
calculated. The Alexa Flour dye content of 8 mol% CMA-modi-
fied copolymer was found to be 0.22 mol%; which is sufficient
for effective detection by confocal microscopy analysis.26
The internalization profile of P(MAA-co-CMA)
Confocal laser scanning microscopy was employed to visualize
the cell uptake profile of the P(MAA-co-CMA) copolymer series
in both human neuroblastoma (SHEP) and human liver hepa-
tocellular carcinoma (HepG2) cell lines. HepG2 cells were
selected due to their well-known cholesterol recognition
profile.27 Cholesterol-based systems have been heavily investi-
gated in the liver28 and liver cells,29,30 where they have shown
encouraging results. SHEP and HepG2 cells were treated with
2 µg ml−1 of Alexa Fluor 488 labelled P(MAA-co-CMA) copoly-
mer series for 1 hour. As seen in Fig. 2, representative Alexa
Fluor 488 labelled 8 mol% CMA copolymers were readily taken
up by both cell lines localizing in the cytoplasm. In line with
previous findings, cell internalization of P(MAA-co-CMA) co-
polymers is influenced by their hydrophobicity (internalization
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increases with higher CMA units).31 It should be noted that
the internalization process of P(MAA-co-CMA) copolymers is
not in any way influenced by modification/labelling as control
flow cytometry studies revealed that both modified and un-
modified polymers displayed the same transfection efficacy.
The internalization mechanism of lipid-based systems are
believed to be driven by endocytosis.9 To determine the
specific endocytic pathway of P(MAA-co-CMA) copolymers,
endocytosis inhibition studies were carried out. CDE and CIE
endocytosis were the two major pathways evaluated utilizing
the common endocytosis inhibitors; chlorpromazine, methyl-
β-cyclodextrin (MβCD) and genistein. Chlorpromazine,
an inhibitor for CDE,32,33 is a cationic amphiphilic drug which
translocates clathrin and its related proteins to intracellular
vesicles thus suppressing the formation of clathrin coated
pits.34 Cholesterol-dependent and caveolae-mediated pathways
are subdivisions of CIE.10 MβCD, a cyclic oligomer of glucopyr-
anoside, reversibly removes steroids from the plasma
membrane as a result inhibits cholesterol-dependent endo-
cytosis.35,36 Caveolae-mediated endocytosis was inhibited by a
tyrosine-kinase inhibitor, genistein.37
A control study investigating the in vitro cytotoxicity profile
of each inhibitor was performed in both SHEP and HepG2
cells. Results indicated the optimal protocol to be 2 hour treat-
ments of endocytic inhibitors at concentration levels of 5 µg
ml−1 chlorpromazine, 2.5 mM MβCD and 300 µM genistein.
Fig. 1 (A) ATR-FTIR spectrums of 8 mol% CMA (grey) and 8 mol% CMA-modified (black) copolymers. (B) UV absorption of standard solutions pre-
pared with 8 mol% CMA in MilliQ water (at 275 nm).
Fig. 2 Confocal microscopy images of (A–B) SHEP and (C–D) HepG2
cells treated with Alexa Fluor 488 labelled 8 mol% CMA copolymers
(2 µg ml−1) in serum media for 1 hour. Alexa Fluor 488 (λex = 495 nm and
λem = 591 nm) was excited using a 485 nm laser. Scale bars correspond
to 10 µm.
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Following inhibitor toxicity studies, confocal microscopy
was employed to assess the specificity of the inhibitors in
relation to the uptake of molecules known to taken up by
specific endocytic routes, Human transferrin (hTF)38 and lacto-
sylceramide (LacCer).39 hTF is known to be taken up via CDE
while LacCer is internalized via CIE where is associated
with lipid rafts.40 Fig. S1 and S2† show the CDE and CIE
inhibitors suppressing the hTF and LacCer uptake in SHEP
and HepG2 cells, respectively. Treating cells with 5 µg ml−1
chlorpromazine 2 hours before hTF addition (Fig. S1-C and
S2-C†) reduced the internalization profile of hTF in compari-
son to control sample (Fig. S1-A and S2-A†). These results dis-
played the inhibitory effect of chlorpromazine on hTF,
verifying its specificity towards CDE along with illuminating
the optimal inhibitor conditions (5 µg ml−1 chlorpromazine
for 2 hours).
Confocal images in Fig. S1-B and S2-B† show the uptake of
LacCer molecules into untreated SHEP and HepG2 cells,
respectively. Inhibition studies utilizing MβCD at 2.5 mM
resulted in a reduction in LacCer internalization into either
cell type (Fig. S1-D and S2-D†). Cell blockage was clearly visual-
ized by the distinct green border surrounding the cell walls
which implied effective inhibition combined with the
reduction in the number of visible vesicles in the cytoplasm.
Consistent with previous MβCD treatments, the cell mor-
phologies slightly changed, which was attributed to cholesterol
depletion and rearrangement of the cytoskeleton.41 Based on
the cell viability data and confocal images 2.5 mM MβCD for
2 hours was the preferential settings for inhibiting CIE. In
accordance with MβCD treatments, genistein also blocked
LacCer uptake to the cells (Fig. S1-E and S2-E†). Interestingly
HepG2 cells showed a higher response to inhibition than
SHEP cells, as they changed their morphology while blocking
the CIE pathway.
After establishing the ideal inhibitor conditions (cells versus
concentration) and confirming the specific uptake mechanism
for each inhibitor; studies investigating the endocytic pathway
of statistical copolymers were subsequently carried out.
Initially, polymer internalization was assessed in correspon-
dence to the CDE uptake mechanism. Confocal images of
P(MAA-co-CMA) uptake in SHEP and HepG2 cells – pre-treated
with chlorpromazine – are shown in Fig. 3(A–B) and 4(A–B),
respectively. Results indicate that the polymer internalization
mechanism was not affected by chlorpromazine treatments, as
they were readily taken up by both cell lines displaying similar
uptake profiles to untreated cells (Fig. 2).
Thereafter, investigations followed the involvement of CIE
pathways on polymer internalization via MβCD and genistein
inhibitors. Fig. 3(C–D) and 4(C–D) shows the uptake of copoly-
mers after a 2 hour MβCD treatment. The pre-incubation of
MβCD in both cell lines, resulted in inhibitory effects for
polymer endocytosis. Owing to the cholesterol moieties, in the
copolymer composition, hydrophobic interactions between the
plasma membrane and P(MAA-co-CMA) were blocked thus pre-
venting cellular internalization from taking place (shown by
yellow arrows).
Lastly, the endocytic pathway of polymers was investigated
after 300 µM genistein treatments in SHEP and HepG2 cells
Fig. 3(E–F) and 4(E–F), respectively. Images indicate that genis-
tein noticeably effects the cellular uptake mechanism of
P(MAA-co-CMA); as the polymers mostly appear on the surface
of plasma membrane (represented by pink arrows).
It is evident from these results that CIE is the main endocy-
tic pathway involved in P(MAA-co-CMA) internalization by
Fig. 3 Evaluation of Alexa Fluor 488 labelled 8 mol% CMA copolymers (2 µg ml−1) uptake in SHEP cells after 2 hour treatments of (A–B) chlorpro-
mazine (5 µg ml−1), (C–D) MβCD (2.5 mM) and (E–F) genistein (300 µM). Alexa Fluor 488 fluorescent images were acquired at λex = 495 nm and
λem = 591 nm. Scale bars represent 10 µm.
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SHEP and HepG2 cells. Polymer uptake was governed solely by
their hydrophobic moieties which is very common with lipid-
based systems.10,40–42 It should be mentioned that a prelimi-
nary quantitative analysis on inhibitory effects was undertaken
by flow cytometry. However, the assay was not feasible as the
desired amount of Alexa Fluor labelled polymer, for sufficient
detection via flow cytometry, was too large to chemically syn-
thesize in a cost-effective and efficient manner.
Characterization studies of P(MAA-co-CMA)–DOX
nanocomplexes
Upon establishing the cellular internalization profile of
P(MAA-co-CMA) series, the anionic copolymers were than
exploited as potential drug delivery systems. DOX, a cationic
anticancer drug,20,21 encompasses amine groups which bestow
cationic properties to the molecule resulting in a pKa value of
8.6.43,44 Owing to these positive charges, DOX molecules are
predicted to instigate electrostatic interactions between the
carboxylic components of P(MAA-co-CMA) series (pKa ∼ 5.0)45
at neutral conditions. Consequently, DOX was selected as a
model chemotherapeutic for examining the complexation
efficiency to P(MAA-co-CMA) series while evaluating the nano-
complexes therapeutic efficacy in a variety of cells.
Fluorescence lifetime imaging microscopy (FLIM) is a
useful tool for differentiating free DOX from its polymer conju-
gated form.46 The fluorescence lifetimes of unbound DOX and
P(MAA-co-CMA)–DOX nanocomplexes in aqueous solution
were measured via time-correlated single photon counting
(TCSPC) and represented in a phasor plot.47,48 The lifetime of
each species is categorized in pixel format and transformed
into a phasor plot by fitting the data to an exponential decay.
All single exponential lifetimes lie on the universal circle while
multi-exponential lifetimes are a linear combination of their
components (Scheme S2, ESI†).
The phasor plot seen in Fig. 5(A–B) shows the difference in
fluorescence lifetime for both free DOX and nanocomplexes
prepared at varying w/w ratios at 0 hours. The free DOX exhi-
bits a lifetime of 1 ns46 and the nanocomplexes at 0 hours
display a dominant longer lifetime verifying P(MAA-co-CMA)–
DOX conjugation as shown by their position in the phasor
plot.49,50
The data indicated that with increasing P(MAA-co-CMA)–
DOX nanocomplexation ratios from 125 : 1 to 1250 : 1 longer
lifetimes were observed in the same region. The stability of the
P(MAA-co-CMA)–DOX nanocomplexes (prepared at varying
ratios 6.25 : 1–1250 : 1) were further examined over a 24 hour
incubation period (Fig. S3, ESI†). The phasor plot shift from
free DOX to nanocomplexes (longer lifetime) within the hour
confirms steady complexation however loss of stability is
observed at 24 hours by the existence of two lifetimes under
the exponential decay.
In agreement with the FLIM data, P(MAA-co-CMA)–DOX
nanocomplexes were prepared in MilliQ water at varying w/w
ratios ranging from 6.25 : 1 to 1250 : 1 and were analysed via
UV-Vis. A representative absorbance spectrum of free DOX
along with P(MAA-co-CMA)–DOX nanocomplex (6.25 : 1) is dis-
played in Fig. 5-C. The DOX spectrum illustrates maximum
absorbance at 480 nm and 2 shoulders at 500 and 535 nm.
P(MAA-co-CMA) complexation resulted in a 10 nm bathochro-
mic shift of λmax in the spectrum, overall decreasing the
optical density of solution.21 π–π stacking interactions between
the DOX molecules and polymers (immobilizing DOX along
the polymer chains) was the reason for bathochromic shift in
the absorbance spectrum, which commonly is seen with
Fig. 4 Intracellular distribution of Alexa Fluor 488 labelled 8 mol% CMA copolymers (2 µg ml−1) after 2 hour treatments of (A–B) chlorpromazine
(5 µg ml−1), (C–D) MβCD (2.5 mM) and (E–F) genistein (300 µM) in HepG2 cells. Alexa Fluor 488 (λex = 495 nm and λem = 591 nm) was excited using
a 488 nm laser. Scale bars represent 10 µm.
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chromophore–polyelectrolyte conjugates evidencing complex
formation.20,51,52
The structure of DOX encompasses an aglycone moiety, a
tetracyclic chromophore where the aromatic rings form a planar
anthraquinone system, which is attached to an amino sugar
daunosamine through glycosidic bonds. The complexation
reactions are believed to be driven by a number of forces
including ionic interactions (mentioned in the previous
section), hydrogen bonding and π–π stacking interactions.
Hydrogen bonding is formed amongst the hydroxyl groups
attached to the anthraquinone ring in DOX and hydroxyl
groups of polymer. π–π stacking interactions are facilitated by
the aromatic rings, in the anthraquinone system, which are
the driving forces of intercalating DNA.51
Accordingly P(MAA-co-CMA)–DOX nanocomplexes were pre-
pared at w/w ratios of 6.25 : 1, 125 : 1 and 1250 : 1 in MilliQ
water. The hydrodynamic diameter, polydispersity index and
ζ-potential of the complexes were determined by DLS studies
(Table 1). Complexes prepared with increasing polymer ratios
displayed a reduction in their effective diameter. Proportional
to the increase of substitutes in the complex, enhancements in
inter/intramolecular forces are also observed. DOX molecules
generally intertwine with the polymer chains through various
interactions forming compact particles.21 With increasing
polymer chains the amount of interactions increase bringing
the constructs closer together, evidently decreasing the overall
diameter of the complex. The zeta potential of the nanocom-
plexes with increasing complexation ratios (from 6.25 to 1250)
exhibited an overall negative charge. A slight decrease in the
zeta potential was observed in the system which was attributed
to the enhancement of anionic carboxyl groups of the polymer
chains in the final nanocomplex.
Toxicity screening of P(MAA-co-CMA)–DOX nanocomplexes
The toxicity profiles of P(MAA-co-CMA)–DOX nanocomplexes
(at 125 : 1 and 1250 : 1 conjugation ratios) in comparison to
free DOX treatments were evaluated in SHEP, HepG2 and
MRC5 cells at 72 hours. Previous cell toxicity studies con-
ducted with P(MAA-co-CMA) copolymer series demonstrated
high levels of viability, between concentrations of 0.05 μM and
50 μM, in the designated cell lines.53 The half-maximal inhibi-
tory concentration (IC50) doses of the polymers were not calcu-
lated due to their exceptionally low toxicity values. The
variance of CMA ratio in the copolymer compositions, did not
exhibit any major differences in toxicity amongst each other,
as polymers or as nanocomplexes (Fig. S4 and S5, ESI†).
The IC50 values of each nanocomplex in each cell line are
represented in Table 2. The MRC5 IC50 values were 2.4-fold
higher for free DOX and between 8-fold (125 : 1) and 12.5-fold
(1250 : 1) higher in the case of P(MAA-co-CMA)–DOX nano-
complexes than those for SHEP cells.
Conversely, the SHEP IC50 values of free DOX treatments
were 3.3-fold higher than the P(MAA-co-CMA)–DOX nano-
Fig. 5 Phasor analysis for P(MAA-co-CMA)–DOX nanocomplexes at (A) 125 : 1 and (B) 1250 : 1 (w/w) ratios at 0 hours. 1.4 µM free DOX was included
as a control sample. (C) UV-Visible spectrum of free DOX and P(MAA-co-CMA)–DOX nanocomplex in MilliQ water at 480 nm.
Table 1 Mean hydrodynamic diameter, polydispersity index (PDI), and
ζ-potential of P(MAA-co-CMA)–DOX nanocomplexes containing 50 µM
DOX at varying complexation ratios
P(MAA-co-CMA)–DOX
nanocomplex Diameter (nm) PDI
ζ-Potential
(mV)
6.25 : 1 113.5 ± 14.2 0.47 ± 0.07 −20.7 ± 1.2
125 : 1 109.4 ± 17.3 0.47 ± 0.02 −23.5 ± 3.1
1250 : 1 62.9 ± 6.3 0.45 ± 0.06 −29.8 ± 0.5
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complexes at both 125 : 1 and 1250 : 1 conjugation ratios, indi-
cating that P(MAA-co-CMA)–DOX nanocomplexes are more
efficient than free DOX in SHEP cells. HepG2 cells demon-
strated a similar trend where the IC50 value of free DOX was
slightly higher than nanocomplexes (125 : 1 and 1250 : 1),
however showed some fluctuations with nanocomplex samples
of 4 mol% CMA and 8 mol% CMA prepared at 1250 : 1 ratio.
This increase can be attributed to the uptake mechanism of
the polymers in HepG2 cells. Internalization via CIE where
endo/lysosomal trafficking is hindered due to the absence of
caveosomes – the signal between cellular compartments –54
may lead to the entrapment of complexes in cell vesicles.55
The high anionic character of the complexes overpowers the
membrane destabilizing properties of the polymer thus result-
ing in engulfed particles incapable of reaching the target site,
nucleus.56
It should be mentioned that HepG2 cells were less suscep-
tible to DOX related treatments owing to their slow growth
rate57 which is not favourable in the case of DOX internali-
zation. In line with previous reports,58,59 the data suggests that
P(MAA-co-CMA)–DOX nanocomplexes demonstrate greater
efficacy than free DOX samples in carcinoma cell lines and
exhibit lesser toxicity in normal cells.
Intracellular uptake of P(MAA-co-CMA)–DOX nanocomplexes
FLIM was employed to characterize uptake of P(MAA-co-CMA)–
DOX nanocomplexes (at 125 : 1 w/w ratio) in live cells. FLIM
images, captured at 1 and 4 hour time-points, displayed two-
different lifetimes in SHEP cells which were associated with
free and conjugated DOX.
The phasor region, associated with P(MAA-co-CMA)–DOX
nanocomplexes in solution (highlighted by the yellow cursor)
represents the longer fluorescence lifetime species. The fluo-
rescence lifetime of the complexes, indicated in yellow, are
shown in the region images pinpointing the exact location of
the complexes in the cell (Fig. 6). The shortest lifetime species
is represented by the green cursor, with this being associated
with free DOX residing in the nucleus and a longer lifetime
species in the cytoplasm as represented by red pixels as
selected with the red cursor in the phasor plot. In the first
4 hours, both P(MAA-co-CMA)–DOX nanocomplexes and
cleaved DOX are present in the cells, where overtime the
released DOX localizes in the nucleus with increasing concen-
trations. In contrast, P(MAA-co-CMA)–DOX nanocomplexes
begin accumulating in the cytoplasm with increasing time.
The shorter fluorescence lifetime becoming more dominant
overtime indicates that DOX is in fact being effectively released
from the P(MAA-co-CMA)–DOX nanocomplexes following their
cellular uptake in a time-dependent manner.50,60
Confocal laser scanning microscopy was conducted to visu-
alize cellular uptake of the P(MAA-co-CMA)–DOX nanocom-
plexes in SHEP, HepG2 and MRC5 cell lines as function of
time. Nanocomplexes, comprising DOX and P(MAA-co-CMA)
were prepared at two conjugation ratios (125 : 1 and 1250 : 1)
and incubated for 1, 4 and 24 hours prior to imaging. The cell
nuclei were stained with 5 μg ml−1 Hoechst 33342. Free DOX
treatments were included merely as control images.
Fig. 7 shows the cellular internalization of nanocomplexes
in SHEP cells over time. Images suggest that complexes are
readily up taken and start localizing in nucleus by 4 hours,
Table 2 IC50 values (µM) of DOX and P(MAA-co-CMA)–DOX nanocom-
plexes in various cell linesa
Nanocomplex
ratios SHEP HepG2 MRC5
DOX 0.36 ± 0.141 0.93 ± 0.014 0.87 ± 0.139
2 mol%
CMA-DOX
125 : 1 0.11 ± 0.006* 0.82 ± 0.135 0.78 ± 0.029
1250 : 1 0.10 ± 0.002* 0.77 ± 0.100 0.90 ± 0.044
4 mol%
CMA-DOX
125 : 1 0.11 ± 0.004* 0.90 ± 0.148 0.82 ± 0.058
1250 : 1 0.10 ± 0.006* 1.77 ± 0.351 1.70 ± 0.183**
8 mol%
CMA-DOX
125 : 1 0.12 ± 0.004* 0.82 ± 0.028 0.71 ± 0.056
1250 : 1 0.12 ± 0.008* 3.07 ± 0.238 1.50 ± 0.367*
a IC50 values for *P(MAA-co-CMA)–DOX treatments (both 125 : 1 and
1250 : 1) in SHEP cells were significantly less than DOX. The
significance between IC50 values for P(MAA–co-CMA)-DOX treatments
in HepG2 cells were DOX vs. 4 mol% CMA-DOX (**), DOX vs. 8 mol%
CMA-DOX (***), 2 mol% CMA-DOX vs. 4 mol% CMA-DOX (**), 2 mol%
CMA-DOX vs. 8 mol% CMA-DOX (***) and 4 mol% CMA-DOX vs. 8 mol%
CMA-DOX (***). IC50 values of **4 mol% CMA-DOX and *8 mol%
CMA-DOX at 1250 : 1 were significantly greater than both DOX and
2 mol% CMA-DOX in MRC5 cells. IC50 values were calculated in graph
pad prism via nonlinear regression analysis. One way Anova with
Tukeys multiple comparisons follow up tests for significance.
Fig. 6 Region of interest (ROI) examined and the corresponding phasor plot of free DOX and P(MAA-co-CMA)–DOX nanocomplexes at 125 : 1 w/w
ratio after 1 hour and 4 hours in SHEP cells.
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while by 24 hours, complexes have broken down further (in
line with FLIM stability data) with a large amount of DOX loca-
lized to the nucleus. Complexes formed with higher polymer
ratio (1250 : 1) presented similar cellular internalization results
at 1 and 4 hours; however at 24 hours viability of the cells was
drastically reduced owing to the high polymer content.
Fig. S6 displays the nanocomplex uptake at 1, 4 and
24 hour intervals in HepG2 cells. In agreement with toxicity
profiles, HepG2 cells are less susceptible to internalization of
P(MAA-co-CMA)–DOX nanocomplexes. This could be attributed
to the difference in internalization mechanism/properties like
rate of nutrient uptake, doubling time and other biochemical
processes between cell lines.56,61,62 The slower growth rate of
HepG257 drives complexes at 125 : 1 to internalize and release
the majority of their load after 4 hours and with nuclear local-
ization visible at 24 hours. Alexa Fluor 488 labelled polymers
were used to verify the complexation between the two com-
ponents and visualize complex localized DOX release at
4 hours (Fig. S6-E, ESI†).
Finally the complex uptake profile was investigated in
MRC5 cells lines over the course of 1 and 4 hours (Fig. S7,
ESI†). Complex treatments showed similar uptake patterns at
same time points attaining the load mostly in the cytoplasm
instead of it target site, nucleus.
The endocytic profile of P(MAA-co-CMA)–DOX nanocomplexes
Flow cytometry was employed to investigate the specific endo-
cytic pathway of the P(MAA-co-CMA)–DOX nanocomplexes pre-
pared at 1250 : 1 (w/w) ratio in SHEP an HepG2 cell lines. A
representative confocal imaging study of SHEP cells investi-
gating the endocytic profile of nanocomplexes can be seen in
Fig. S8, ESI.† Cells were treated with nanocomplexes in the
presence of the pharmacological inhibitors – genistein, chlor-
promazine and MβCD – to block CDE and CIE pathways.9
Fig. 8 illustrates the cellular inhibition of nanocomplex uptake
as detected from the fluorescence intensity of DOX. A control
set, evaluating free DOX uptake in the presence of inhibitors,
resulted in no inhibitory effects which is due to the fact that
the cellular uptake process of DOX is governed by passive
diffusion rather than endocytosis (data not included).63,64 The
endocytic pathway of the P(MAA-co-CMA) copolymers alone
were shown to be CIE due to the cholesterol units in their
polymer-chain; while the nanocomplexes demonstrated altered
mechanisms of uptake which could be attributed to the
Fig. 7 Confocal laser scanning microscopy exhibiting cellular internalization of 0.5 µM DOX and P(MAA-co-CMA)–DOX nanocomplexes at conju-
gation ratios of 125 : 1 and 1250 : 1 within (A–C) 1 hour, (D–F) 4 hours and (G–I) 24 hours in SHEP cells. Nuclei (represented in blue) were visualized
with Hoechst 33342 stain. DOX fluorescent images were acquired at λex = 485 nm and λem = 595 nm (visualized in red). Scale bars are used to indi-
cate 10 µm.
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change in size, charge density, and self-assembly that occurred
with DOX complexation.
The efficacy of endocytic inhibitors are known to drastically
differ between cell lines.56,65 The variance between SHEP and
HepG2 cells metabolism, growth rate and cell morphologies
cause these inhibitors to display different expression profiles.
The pre-treatment of genistein, a tyrosine kinase inhibitor that
disrupts the actin network of and cells and inhibits dynamin
II the master regulator of membrane trafficking,66 demon-
strated contrasting uptake profiles for both cell lines. The
rearrangement of the actin cytoskeleton and disruption of
ligand triggered uptake in SHEP cells decreased the cellular
internalization profile of P(MAA-co-CMA)–DOX nanocomplexes
by 54.4%. This inhibition profile suggests that nanocomplexes
take a ligand triggered caveolae-mediated route while interna-
lizing in to SHEP cells. Owing to the slower metabolic rate of
HepG2 cells neither the internalization rate – as seen in toxi-
city and microscopy studies – nor the inhibition profile of
nanocomplexes in SHEP cells are the same. It can be specu-
lated that the delay in rearranging the actin network of HepG2
cells may have caused leakiness in membrane surface thus
allowing nanocomplexes to be taken up through diffusion
rather than endocytosis. No significant inhibition data was
detected with MβCD treatments hinting nanocomplexes to
favour either CIE or CDE mechanisms in both cells. The CDE
pathway was investigated through chlorpromazine treatments,
where the internalization of nanocomplexes was significantly
reduced by 33.4% and 17.4% in SHEP and HepG2 cells,
respectively.
The whole data suggests that both CDE and caveolae-
mediated mechanisms influence the uptake of P(MAA-co-
CMA)–DOX nanocomplexes in SHEP cells, with caveolae-
mediated endocytosis contributing to cellular internalization
to a greater degree. This is a common occurrence with pharma-
cological endocytic pathway inhibition; in the event of block-
ing one pathway cells are able to adapt and up-regulate by
another internalization mechanism,8,32,36 and in our case
demonstrate multiple endocytic pathways.8,67,68 Caveolae-
mediated endocytosis, the dominant uptake mechanism, was
strongly influenced by both hydrophobic interactions and size
effects.11 While cholesterol moieties on polymer chains gov-
erned interactions with glycosphingolipid rich microdomains
on the plasma membrane, the average nanocomplex diameter
(62 nm at 1250 : 1 ratio) coincided with the size of caveolae
invaginations in the cell membrane (50–80 nm) thus eviden-
cing caveosomes as the primary endocytic mechanism.32,69
Overall, caveolae-mediated endocytosis is the principle
pathway for P(MAA-co-CMA) internalization which has the
potential to override the mechanisms involved in P(MAA-co-
CMA)–DOX nanocomplex cellular uptake (as it showed higher
inhibition profile). The caveolae-mediated endocytosis process
offers a significant advantage of transcytosing its load across
the cells efficiently with the potential of enhancing deep tissue
and vascular penetration of its cargo drugs.8,70
Experimental
Materials
The synthesis of cholesterol methacrylate (CMA) and the RAFT
polymerization of P(MAA-co-CMA) copolymer series (2 mol%
CMA, cholesterol content 2 mol%, with number average mole-
cular weight (Mn)GPC of 16 500 g mol
−1 and polydispersity
index (PDI) of 1.19; 4 mol% CMA, cholesterol content 4 mol%,
with (Mn)GPC 15 800 g mol
−1 and PDI 1.10; 8 mol% CMA,
cholesterol content 8 mol%, with (Mn)GPC 18 000 g mol
−1 and
PDI 1.11) have been previously described.31,71 DBL® Doxorubi-
cin hydrochloride (DOX) and N-hydroxysulfosuccinimide
(NHS-sulfo) were obtained from Hospira Australia Pty Ltd and
Thermo Scientific, respectively. Ethyl (dimethylaminopropyl)
carbodiimide (EDC), tris(2-carboxyethyl) phosphine (TCEP),
cystamine dihydrochloride, phosphate buffered saline (PBS),
poly-D-lysine hydrobromide, bisBenzimide H 33342 trihy-
drochloride (Hoechst 33342), genistein, methyl-β-cyclodextrin
and chlorpromazine hydrochloride were purchased from
Sigma-Aldrich. Dulbecco’s Modified Eagle Medium (DMEM)
Fig. 8 Inhibition of P(MAA-co-CMA)–DOX nanocomplexes after incubation with endocytic inhibitors (300 µM genistein, 5 µg ml−1 chlorpromazine
and 2.5 mM MβCD for 2 hours) in (A) SHEP and (B) HepG2 cells determined by Flow Cytometry.
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with 4.5 g L−1 glucose and L-glutamine, heat inactivated Foetal
Calf Serum (FCS), trypsin solution (0.25% (w/v) trypsin in
Hank’s solution), Trypan Blue and OptiMEM® I Reduced
Serum Medium were obtained from Invitrogen Life Techno-
logies. Transferrin from human serum AlexaFlour®647 conju-
gate, BODIPY® FLC5-lactosylceramide complexed to BSA and
Alexa Fluor® 488 maleimide dye were purchased from Invitro-
gen Molecular Probes™.
Instruments
Fourier transform infrared spectrometer. Attenuated Total
Reflection-Fourier Transform Infrared Spectroscopy
(ATR-FTIR) measurement was obtained by a Bruker IFS66/S
High End FT-NIR/IR Spectrometer system using diffuse reflec-
tance sampling accessories and a resolution of 4 cm−1. The
spectrum for the copolymer was recorded in the region of 500
to 5000 cm−1 using 256 scans.
UV-Visible spectrophotometer. UV-Visible (UV-Vis) spectra
were obtained by a double beam Hitachi – UV spectrometer
(Model no: U-2800) using UV solutions 2.1 software. The
instrument was equipped with a double beam light source car-
rying a detection range from 190 nm to 1100 nm and a photo-
metric range of 5 absorbance units. The absorbance of
copolymer solutions were measured at 400 nm while P(MAA-
co-CMA)–DOX nanocomplexes were analysed at 485 nm using
quartz cuvettes.
Dynamic light scattering. Dynamic light scattering (DLS)
studies and ζ-potential measurements were performed using a
Malvern Zetasizer NaNo ZS Instrument (Malvern, USA)
equipped with a 4 mV He–Ne laser operating at λ = 633 nm, an
avalanche photodiode detector with high quantum efficiency,
and an ALV/LSE-5003 multiple tau digital correlator electronics
system. Size measurements were performed in Disposable
Solvent Resistant Micro Cuvettes ZEN0040 (Malvern Instru-
ments) recorded in nanometres (nm) while charge readings
were conducted in Folded Capillary Cells DTS1060 (Malvern
Instruments) shown in millivolts (mV). The dispersant para-
meters used for the analyses were RI: 1.330, Abs: 0.01 and
diluent (water) viscosity: 0.88 cP. The P(MAA-co-CMA)–DOX
sample solutions were prepared in MilliQ water with a fixed
DOX concentration of 50 µM at varying complexation ratios.
All samples were measured by scanning 7 times with each
time of automatic measurement. Assays were done in
duplicates.
Flow cytometer. Falcon 5 mL polystyrene round bottom
tubes (12 mm × 75 mm) were used for cell collection and pur-
chased from Becton Dickinson. A FACSCanto™ flow cytometer
(Becton-Dickinson) equipped with BD Biosciences FACSDiva
Software was used for cell cycle analysis. The flow rate was
<200 nuclei and 10 000 cells for each sample were analyzed.
The CellQuest program was used to quantitate the distribution
of cells in each cell cycle phase.
Fluorescence lifetime imaging microscopy. Fluorescence
lifetime imaging (FLIM) was performed on a Microtime200
inverted confocal microscope (PicoQuant GmbH) equipped
with a 60 × 1.2 NA water-immersion objective and a field-of-
view area of 80 × 80 microns. Excitation was achieved by a
fiber-coupled picosecond-pulsed, variable-repetition-rate diode
laser operating at 470 nm with a pulse width below 200 ps.
The emission was collected using a 550 nm long-pass filter
and a single-photon avalanche diode (SPAD) (PDM, Micro-
Photon Devices) coupled to time-correlated single-photon
counting (TCSPC) electronics (Picoharp300, PicoQuant).
SymphoTime Software (PicoQuant) was utilized for data
acquisition. The SIMFCS Software, which was developed at
the Laboratory for Fluorescence Dynamics (University of
California), was employed for phasor analysis of the attained
FLIM data.
Methods
Fluorescent labelling of P(MAA-co-CMA) copolymers. 2 mol%
of the carboxylic acid groups on each P(MAA-co-CMA)
sample was targeted and modified according to the protocol
described in literature.25 A model calculation for polymer
modifications and labelling is as follows: Purified 8 mol%
CMA (5 mg, 32.7 µmol carboxylate groups) was dissolved in
1 mL buffer (0.1 M sodium phosphate buffer, pH 7.5), yielding
a polymer solution of 0.30 mM. The polymer was reacted with
2-fold molar excess of EDC/NHS-sulfo (0.62 µmol/1.62 µmol) at
room temperature for 15 minutes. The pH of the reaction
mixture was adjusted to 7.0 then supplemented with 10-fold
molar excess of cystamine dihydrochloride (30 mM). The reac-
tion continued in room temperature for 2 hours at pH 7.0.
Upon completion the polymer was purified by dialysis (against
MilliQ water) for 2 days. The product was freeze dried and ana-
lysed via FTIR.
ATR-FTIR (cm−1) for 8 mol% CMA: 3400–2900 (carboxylic
acid O–H stretching), 3100–2700 (alkene and alkane C–H
stretching), 1735–1650 (CvO ester stretching), 1630–1550 (car-
boxyl anions CvO stretching), 1170 (C–O–C stretching),
900–644 (aromatic C–H bending).
ATR-FTIR (cm−1) for 8 mol% CMA-modified: 3400–2900 (car-
boxylic acid O–H stretching), 3100–2700 (alkene and alkane
C–H stretching), 1735–1650 (CvO ester stretching), 1650–1580
(N–H bend), 1020–1220 (aliphatic amines), 1160 (C–O–C stretch-
ing), 900–644 (aromatic C–H bending) (Fig. 1-A).
0.5 mg of the modified polymer was dissolved in 50 µL
phosphate buffer solution (pH 7.8). 14 µL of Alexa Fluor® 488,
a fluorescent maleimide dye, (stock solution 20 mM) was
included to the polymer solution resulting in a 4-fold molar
excess to thiol-reactive groups. At the beginning of the reaction
15 mg of tris(2-carboxyethyl) phosphine (TCEP) (15-fold
excess) was dissolved into this mixture to reduce the disul-
phide bonds of cystamine dihydrochloride. 2 hours later
another 15 mg of TCEP was supplemented to the mixture
allowing the reaction to proceed for an additional 3 hours. The
product was purified by dialysis (against MilliQ water) in the
dark for 3 days. In line with previous detection studies,72
UV-Vis investigations of P(MAA-co-CMA) copolymers revealed a
distinctive peak at 275 nm, which enhanced with increasing
CMA moieties, evidencing the short wavelength to be specific
to cholesterol units in the composition. Accordingly the fluo-
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rescent dye content of 8 mol% CMA was quantified by UV-Vis
spectrometer analysis, where a calibration curve was built from
standard solutions of 8 mol% CMA in MilliQ water at 275 nm
(Fig. 1-B).
Preparation and characterization of P(MAA-co-CMA)–DOX
nanocomplexes. DOX was dissolved in MilliQ water at a final
concentration of 0.8 µg ml−1. P(MAA-co-CMA) copolymer solu-
tions, prepared in MilliQ water, were added to the DOX solu-
tion at equal volume to form final complex (P(MAA-co-CMA)–
DOX) ratios of 1 : 1, 6.25 : 1, 12.5 : 1, 62.5 : 1, 125 : 1, 625 : 1,
1250 : 1, and 6250 : 1 w/w. Owing to the strong electrostatic
interaction a 5 minute complexation period in the dark
resulted in instant complexation. Nanocomplex formation was
analysed by FLIM and UV-Vis Spectroscopy. The hydrodynamic
mean diameter and zeta potential of the P(MAA-co-CMA)–DOX
nanocomplexes was measured by DLS at a wavelength of
633 nm with a 90° detection angle at 25 °C.
Toxicity screening of P(MAA-co-CMA)–DOX nanocomplexes.
The toxicity profile of free DOX and P(MAA-co-CMA)–DOX
nanocomplexes was evaluated in human neuroblastoma
SHEP cells, human liver hepatocellular carcinoma (HepG2)
cells and human foetal lung fibroblast MRC5 cells by an
Alamar Blue73 assay. Cells were seeded in 96-well flat-bottom
plates at concentrations of 5 × 103 cells per well for SHEP,
10 × 103 cells per well for HepG2 and 5 × 103 cells per well for
MRC5 and incubated at 37 °C in 5% CO2 and 95%
humidity for 24 hours. After surface adherence, cells were
treated with free DOX and nanocomplexes – at 2 different com-
plexation (w/w) ratios – over an equivalent DOX concentration
range of 0.005 µM–5 µM for 72 hours. Following the incu-
bation period, treatments were removed and replaced with
100 µL fresh media and 20 µL of Alamar Blue per well and
further incubated for another 6 hours. Cell viability was
assessed by comparing treated cells to positive control cells
(100% viability).
Fluorescence microscopy imaging. Cells (5000–7000 cells
per dish) were plated in 35 mm cultured dishes which were
pre-coated with poly-D-lysine hydrobromide for 5 minutes.
After 72 hours of surface adherence, cells were transfected
with P(MAA-co-CMA)–DOX conjugates – at various complexa-
tion ratios – for 1, 4 and/or 24 hours. Transfected cells were
rinsed with PBS and then stained with a nuclear dye (5 μg
ml−1 bisBenzimide H 33342 trihydrochloride (Hoechst 33342))
for 5 minutes. An inverted confocal laser scanning microscope;
Zeiss LSM 780, equipped with an environmental chamber
which controls the atmospheric conditions, humidity and
temperature, was utilized for capturing live-cell images. The
confocal microscope was fitted with a 63× 1.4 NA water objec-
tive that included multiple laser lines (405, 458, 488, 514, 561,
and 633 nm) for fluorescence measurements.
Statistical analysis. Single factor analysis of variance
(ANOVA) with a Tukeys multiple comparison follow up was
employed for statistical analysis of comparative data. Results
were expressed as means of at least three independent experi-
ments ± SD where *P < 0.05, **P < 0.01, ***P < 0.005 values
were considered statistically significant.
Conclusions
In conclusion, P(MAA-co-CMA) copolymer series, with varying
cholesterol units, were evaluated for their endocytic profile
and therapeutic efficiency. P(MAA-co-CMA) copolymers were
modified via EDC/NHS-sulfo reactions and fluorescently
labelled with Alexa Fluor® 488 for imaging and endocytic inhi-
bition studies. The cellular internalization pathway of P(MAA-
co-CMA) copolymers was discovered to be clathrin-indepen-
dent endocytosis (caveolae mediated and cholesterol depen-
dent endocytosis) in both SHEP and HepG2 cell lines. Initial
characterization via FLIM, UV-Vis and DLS verified the ionic
complexation between P(MAA-co-CMA)–DOX nanocomplexes at
varying w/w ratios. The nanocomplexes showed a more pro-
nounced cytotoxicity in SHEP cells in comparison to HepG2
and MRC5 cells while displaying 3.3-fold lower IC50 values
than free-DOX treatments. The cellular uptake profile of
P(MAA-co-CMA)–DOX nanocomplexes, investigated via FLIM
and confocal microscopy, showed DOX accumulation in the
nucleus over time. Endocytic inhibition studies were per-
formed to discover the specific uptake mechanism of the
nanocomplexes. Flow cytometry and confocal microscopy
results indicated the nanocomplexes to be involved in multiple
endocytic pathways with caveolae-mediated uptake being the
dominant mechanism in SHEP cells. The therapeutic profile
of P(MAA-co-CMA) copolymers, reported herein, indicates that
these nano-sized constructs are suited to drug delivery appli-
cations and further polymer modifications could enhance
their efficacy in in vivo treatments.
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